Global Drugs of Abuse (DOA) Testing Market – Industry Trends and Forecast to 2030

Global Drugs of Abuse (DOA) Testing Market, By Product (Consumables, Analyzers, Equipment), Sample Type (Urine, Saliva, Hair, Others), Application (Pain Management, Criminal Justice, Workplace Screening), End Users (Hospitals, Laboratories, Workplace, At Home, Others) – Industry Trends and Forecast to 2030.

 Drugs of Abuse (DOA) Testing Market Analysis and Size

According to the United Nations Office on Drugs and Crime's World Drug Report 2017, the annual prevalence of all illicit drug use is 5.3%, with 255 million users. This will necessitate the need for DOA testing, propelling the market forward. The government's initiatives to raise awareness about DOA and increase organizational compliance for DOA testing will contribute to the overall market's growth. The high demand for products with increased specificity and sensitivity to designer drugs will also contribute to the expansion of the Drug of Abuse (DOA) testing market.     

Data Bridge Market Research analyses that the drugs of abuse (DOA) testing market, which is USD 6253.25 million in 2022, is expected to reach USD 13650.06 million by 2030, at a CAGR of 10.25% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Drugs of Abuse (DOA) Testing Market Scope and Segmentation  

Market Definition

Drug of Abuse testing is a clinical screening procedure used to detect one or more illegal substances such as a drug, chemical, or plant product the patient is addicted to. This clinical screening method uses the patient's urine, saliva, blood, hair, or sweat.

Drugs of Abuse (DOA) Testing Market Dynamics

Drivers

• Increase in consumption and trade of illicit drugs

The increased production, consumption, and trade of new and illicit drugs will result in a high demand for DoA testing, driving industry growth. According to the United Nations Office on Drugs and Crime's World Drug Report 2017, the annual prevalence of all illicit drug use is 5.3%, with 255 million users in 2015. This will necessitate the need for DOA testing, propelling the market forward. The government's initiatives to raise awareness about DOA and increase organizational compliance for DOA testing will contribute to the overall market's growth. The high demand for products with increased specificity and sensitivity to designer drugs will also contribute to the industry's growth.

• Technological advancements and product portfolio expansion

To maintain their competency and market share, leading players in the DoA testing market are expanding their product portfolio through product additions and software updates with new substances for DoA testing. For instance, Shimadzu Corporation, released its Smart Forensic Database Ver. 2 in February 2018, with features for analysing forensic toxicological substances involved in DoA in biological samples using Gas Chromatograph-Mass Spectrometry. Similarly, Thermo Fisher Scientific Inc. updated its library for the Thermo Scientific TruNarc handheld narcotics analyzer in November 2017. The update added 45 new substances to the handheld narcotics analyzer, including 14 new forms of fentanyl, and it can now detect Carfentanil.

Opportunities

• Rising ageing population

According to data published by the Organization for Economic Cooperation and Development (OECD) in 2020, nearly one-third of adults in the European Union aged 15-64, or approximately 97 million people, have used illicit drugs at some point in their lives, with men reporting drug use more frequently than women. To maintain their competency and market shares, leading players in the drug abuse testing market are expanding their product portfolios by adding new products and updating software with new substances for drug abuse testing. These are the certain reasons for propelling the market growth.

Restraints/Challenges

• Inability of testing products to detect small amounts of special drugs

The inability of these testing products to detect small amounts of special drugs is expected to hamper the market growth. In the forecast period of 2023-2030, the transformation of laws to legalize the use of recreational drugs/illicit drugs is expected to challenge the drugs of abuse (DOA) testing market.

This drugs of abuse (DOA) testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drugs of abuse (DOA) testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, WellCare Health Plans introduced new clinical coverage guidelines and claims payment policy for urine drug testing, including definitive urine drug testing as medically necessary as part of a routine monitoring programme for individuals receiving treatment for chronic pain with prescription opioid or other potentially abused medications, or those undergoing treatment for, or monitoring for relapse of, opioid addiction or substance use disorder.
• In 2022, the Delaware Division of Public Health began including fentanyl strips in Narcan kits for public distribution. The initiative was part of a harm-reduction strategy aimed at preventing accidental fentanyl overdoses.

Global Drugs of Abuse (DOA) Testing Market Scope

The drugs of abuse (DOA) testing market is segmented on the basis of product, sample type, application and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumables
• Rapid test kits
• Assay kits
• Reagents
• Others
• Blood
• Breath
• Analyzers
• Equipment
• Immunoassay analyzers
• Chromatography instruments
• Breath analyzers

 Sample Type

• Urine
• Saliva
• Hair
• Others

 Application

• Pain Management
• Criminal Justice
• Workplace Screening

 End Users

• Hospitals
• Laboratories
• Workplace
• At Home
• Others

Drugs of Abuse (DOA) Testing Market Regional Analysis/Insights

The drugs of abuse (DOA) testing market is analyzed and market size insights and trends are provided by country, product, sample type, application and end users as referenced above.

The countries covered in the drugs of abuse (DOA) testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the drugs of abuse (DOA) testing market due to the region's high availability of illegal substances, rising drug trafficking, and more workplace monitoring for drug use.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the region's rising use of illegal substances and rise in organizational adherence to workplace drug testing.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The drugs of abuse (DOA) testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for drugs of abuse (DOA) testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the drugs of abuse (DOA) testing market. The data is available for historic period 2011-2021.

Competitive Landscape and Drugs of Abuse (DOA) Testing Market Share Analysis

The drugs of abuse (DOA) testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to drugs of abuse (DOA) testing market.

Some of the major players operating in the drugs of abuse (DOA) testing market are:

• Takeda Pharmaceutical Company Limited (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• BD (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• GSK Plc. (U.K.)
• Bayer AG (Germany)
• Zimmer Biomet (U.S.)
• Stryker Corporation (U.S.)
• Homology Medicines, Inc (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• JCR Pharmaceuticals Co., Ltd. (Japan)
• Sangamo Therapeutics (U.S.)
• AVROBIO, Inc (U.S.)
• REGENXBIO Inc (U.S)
• CANbridge Life Sciences Ltd. (Taiwan)
• Denali Therapeutics (U.S.)
• Jasper Therapeutics, Inc. (U.S.)